Earnings summaries and quarterly performance for DEXCOM.
Executive leadership at DEXCOM.
Kevin Sayer
Detailed
Chief Executive Officer
CEO
Jake Leach
Detailed
President and Chief Operating Officer
Jereme Sylvain
Detailed
Executive Vice President, Chief Financial Officer
Michael Brown
Detailed
Executive Vice President, Chief Legal Officer
Sadie Stern
Detailed
Executive Vice President, Chief Human Resources Officer
Board of directors at DEXCOM.
Bridgette Heller
Detailed
Director
Euan Ashley
Detailed
Director
Kyle Malady
Detailed
Director
Mark Foletta
Detailed
Lead Independent Director and Interim Chair of the Board
Nicholas Augustinos
Detailed
Director
Renée Galá
Detailed
Director
Richard Collins
Detailed
Director
Rimma Driscoll
Detailed
Director
Steven Altman
Detailed
Director
Research analysts who have asked questions during DEXCOM earnings calls.
Jayson Bedford
Raymond James
6 questions for DXCM
Also covers: AXGN, IART, ICUI +7 more
Joanne Wuensch
Citigroup Inc.
6 questions for DXCM
Also covers: ABT, BAX, BDX +18 more
Marie Thibault
BTIG
6 questions for DXCM
Also covers: ABT, ARAY, ATRC +15 more
Travis Steed
Bank of America
6 questions for DXCM
Also covers: ABT, AXNX, BAX +19 more
Michael Polark
Wolfe Research
5 questions for DXCM
Also covers: BSX, EMBC, INSP +11 more
Shagun Singh Chadha
RBC Capital Markets
5 questions for DXCM
Also covers: AXNX, GMED, INSP +11 more
Danielle Antalffy
UBS Group AG
4 questions for DXCM
Also covers: ABT, ATRC, BAX +15 more
Issie Kirby
Redburn Atlantic
4 questions for DXCM
Also covers: ALC, COO, PODD +1 more
Joshua Jennings
TD Cowen
4 questions for DXCM
Also covers: ABT, ALUR, ATEC +20 more
Steven Lichtman
Oppenheimer & Co. Inc.
4 questions for DXCM
Also covers: ALC, ANGO, COO +12 more
Anthony Petrone
Mizuho Group
3 questions for DXCM
Also covers: ADMA, ALC, BSX +22 more
Bill Plovanic
Canaccord Genuity
3 questions for DXCM
Also covers: AORT, CBLL, IRTC +6 more
Brandon Vazquez
William Blair & Company, L.L.C.
3 questions for DXCM
Also covers: ALGN, CBLL, CVRX +16 more
Christopher Pasquale
Nephron Research
3 questions for DXCM
Also covers: ALC, AXGN, BSX +12 more
David Roman
Goldman Sachs Group Inc.
3 questions for DXCM
Also covers: ABT, BAX, BDX +18 more
Jeffrey Johnson
Robert W. Baird & Co. Inc.
3 questions for DXCM
Also covers: ALC, ALGN, BBNX +11 more
Larry Biegelsen
Wells Fargo & Company
3 questions for DXCM
Also covers: ABT, ALC, AXNX +24 more
Matthew O'Brien
Piper Sandler & Co.
3 questions for DXCM
Also covers: APYX, ATEC, ATRC +18 more
Matthew Taylor
Jefferies
3 questions for DXCM
Also covers: ALUR, BDX, CQP +18 more
Matt Taylor
Jefferies & Company Inc.
3 questions for DXCM
Also covers: BAX, BIO, ESTA +10 more
Michael Kratky
Leerink Partners
3 questions for DXCM
Also covers: AXGN, BBNX, INSP +6 more
Richard Newitter
Truist Securities
3 questions for DXCM
Also covers: AXNX, GKOS, GMED +18 more
Robbie Marcus
JPMorgan Chase & Co.
3 questions for DXCM
Also covers: ABT, BAX, BDX +9 more
Robert Marcus
JPMorgan Chase & Co.
3 questions for DXCM
Also covers: ABT, BAX, BDX +21 more
William Plovanic
Canaccord Genuity
3 questions for DXCM
Also covers: ATRC, CBLL, CVRX +9 more
Danielle Antalffy
UBS
2 questions for DXCM
Also covers: ATRC, BSX, JNJ
Jon Block
Stifel, Nicolaus & Company, Incorporated
2 questions for DXCM
Also covers: COO, ELAN, NYXH +1 more
Matthew Miksic
Barclays PLC
2 questions for DXCM
Also covers: ABT, ATEC, BAX +15 more
Matthew O'Brien
Piper Sandler
2 questions for DXCM
Also covers: ITGR, KMTS
Matt Miksic
Barclays Investment Bank
2 questions for DXCM
Also covers: ABT, ATEC, BAX +14 more
Mike Kratky
Leerink Partners
2 questions for DXCM
Also covers: AXGN, INSP, MDT +4 more
Colin Clark
Stifel Financial Corp.
1 question for DXCM
Also covers: INGN
Kyle Rose
Piper Sandler
1 question for DXCM
Also covers: STIM
Larry Beagleson
Wells Fargo
1 question for DXCM
Also covers: SYK
Lawrence Biegelsen
Wells Fargo
1 question for DXCM
Also covers: ABT, ALC, BAX +16 more
Margaret Kaczor Andrew
William Blair
1 question for DXCM
Also covers: CUTR, NARI, PODD +2 more
Mathew Blackman
Stifel
1 question for DXCM
Also covers: AHCO, ATEC, BBNX +7 more
Matt O'Brien
Piper Sandler Companies
1 question for DXCM
Also covers: BBNX, BSX, GMED +6 more
Mike Polark
Wolfe Research, LLC
1 question for DXCM
Also covers: BBNX, BSX, EMBC +6 more
Patrick Wood
Morgan Stanley
1 question for DXCM
Also covers: ALC, BDX, BLCO +17 more
Simran
Wells Fargo & Company
1 question for DXCM
Also covers: PODD, XRAY
Recent press releases and 8-K filings for DXCM.
Dexcom receives FDA clearance for Smart Basal insulin optimizer
DXCM
Product Launch
- Dexcom secured FDA clearance for Smart Basal, the first CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes on glargine U-100 therapy.
- The system leverages data from the Dexcom G7 15-Day sensor and user-logged insulin doses to provide personalized daily basal dose recommendations, reducing trial-and-error and hypoglycemia fears.
- Smart Basal automatically lowers dose suggestions after hypoglycemic events by a provider-defined amount, enhancing safety.
- Healthcare providers can prescribe and configure Smart Basal via Dexcom Clarity, with recommendations delivered through the Dexcom G7 app for streamlined patient use.
Nov 19, 2025, 4:24 PM
DexCom shareholders eligible for class action alleging unauthorized device changes
DXCM
Legal Proceedings
- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that the deadline to move for lead plaintiff in the DexCom (NASDAQ: DXCM) securities class action is December 26, 2025; the Class Period runs from July 26, 2024 to September 17, 2025.
- The lawsuit alleges DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring devices without FDA approval, overstating their reliability and downplaying health risks.
- Key events include a March 10, 2025 FDA Warning Letter citing “adulteration” of G6/G7 sensors—stock fell $7.12 to $70.72—and subsequent declines on public disclosures and a September 2025 Hunterbrook report revealing device failures and fatalities.
- Investors who acquired DexCom securities during the Class Period should submit their application by the December 26, 2025 deadline to participate in the litigation.
Nov 11, 2025, 2:18 PM
Dexcom faces securities class action over G7 accuracy allegations
DXCM
Legal Proceedings
- BLB&G filed a securities class action in the U.S. District Court for the S.D.N.Y. against Dexcom and certain executives for alleged violations of federal securities laws.
- The suit alleges Dexcom misrepresented the accuracy and reliability of its G7 continuous glucose monitoring device, attributing its success to product quality while concealing defects.
- Plaintiffs claim these defects arose from an unapproved sensor coating change in December 2023, which impaired both sensor accuracy and data transmission.
- The action, related to Prime v. DexCom, covers investors who acquired Dexcom common stock between January 8, 2024 and September 17, 2025.
Nov 10, 2025, 10:00 PM
DexCom shareholders urged to join federal securities class action
DXCM
Legal Proceedings
- A federal securities class action has been filed against DexCom covering July 26, 2024–September 17, 2025, alleging unauthorized design changes and overstated accuracy of its G6 and G7 devices.
- The FDA’s March 10, 2025 Warning Letter prompted a 9.15% stock decline to $70.72 amid concerns over adulterated sensors.
- Further negative catalysts included an Oppenheimer downgrade on September 8, 2025 and a Hunterbrook report on September 18, 2025 highlighting serious reliability issues.
- Investors have until December 26, 2025 to seek lead-plaintiff status; affected shareholders should contact Wolf Haldenstein immediately.
Nov 10, 2025, 4:47 PM
DexCom faces class action over unauthorized monitor design changes
DXCM
Legal Proceedings
- Lawsuits allege DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitors, reducing reliability and posing health risks while overstating G7 accuracy.
- DexCom received an FDA warning letter on March 7, 2025, regarding manufacturing and quality control, triggering a $7.12 stock price decline.
- The class action, Prime v. DexCom, Inc., et al., No. 1:25-cv-08912 in SDNY, asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act.
- Investors who suffered losses from July 26, 2024, to September 17, 2025, may join the lawsuits and seek lead plaintiff status by late December 2025.
Nov 10, 2025, 4:49 AM
Dexcom expands RAMQ coverage of CGM in Québec
DXCM
- Québec’s Régie de l’assurance maladie du Québec now covers Dexcom Continuous Glucose Monitoring for eligible residents 18 and older with type 2 diabetes on intensive insulin therapy, broadening access beyond type 1 patients.
- Dexcom G7 is highlighted as the most accurate CGM system and the #1 preferred by Canadian endocrinologists, with 88% of users reporting improved lifestyle management4.
- All private insurers in Québec must offer coverage at least equivalent to RAMQ criteria, with most already covering CGM for insulin users or all people with diabetes.
- RAMQ eligibility for adults requires ≥3 daily insulin injections or pump therapy plus at least one of: unmet HbA1c targets, frequent hypoglycemia, or unrecognized low-blood-sugar events.
Nov 7, 2025, 1:34 AM
DexCom investors notified of class action lawsuit
DXCM
Legal Proceedings
- Levi & Korsinsky has initiated a class action securities lawsuit against DexCom on behalf of investors alleging fraud from July 26, 2024 to September 17, 2025.
- The complaint alleges unauthorized design modifications to the G6 and G7 glucose monitoring systems that compromised accuracy and reliability and overstated device enhancements.
- Investors must submit a request to be appointed as lead plaintiff by December 26, 2025, and participation incurs no out-of-pocket costs.
Nov 6, 2025, 9:26 PM
Dexcom expands Quebec RAMQ coverage for CGM system
DXCM
- The Régie de l’assurance maladie du Québec (RAMQ) now covers Dexcom’s continuous glucose monitoring (CGM) system for Quebec residents aged 18+ with type 2 diabetes on intensive insulin therapy.
- Private insurance plans must offer coverage at least equivalent to RAMQ criteria, with most already covering Dexcom CGM for insulin users.
- The Dexcom G7 CGM is noted as the most accurate and preferred by Canadian endocrinologists, and 88% of type 2 users report it helps them better adjust their lifestyle.
Nov 6, 2025, 2:00 PM
DexCom investors advised of class action lawsuit
DXCM
Legal Proceedings
- Kirby McInerney LLP is investigating a securities fraud class action for investors who purchased DexCom shares between July 26, 2024 and September 17, 2025.
- The lawsuit alleges unauthorized design changes to the G6 and G7 devices overstated their reliability and concealed health risks, exposing DexCom to increased regulatory scrutiny.
- DexCom disclosed on March 7, 2025 that it received an FDA warning letter over manufacturing and quality control issues, triggering a 9.15% share price drop from $77.84 to $70.72 by March 10.
- On March 25, 2025, the FDA published the warning letter, revealing adulteration of sensor modifications that caused larger inaccuracies and higher user risks, leading shares to decline 2.4% to $73.55.
Nov 5, 2025, 11:00 PM
Dexcom: Smart Home Healthcare Market Forecast to Reach $796.03B by 2034
DXCM
- 2024 market size $96.44 B; projected to reach $796.03 B by 2034 at a 23.5% CAGR (2025–2034)
- Growth driven by an aging population, rising chronic diseases—e.g., over 800 million with diabetes—and IoT/AI integrations
- Smart glucose monitoring systems set to dominate the market amid advances in wearable tech
- North America accounted for ≈45% of revenue share in 2024, led by strong digital health infrastructure
- Leading players include Honeywell, Siemens Healthineers, Philips, Qualcomm and Dexcom, Inc.
Nov 4, 2025, 12:53 PM
Quarterly earnings call transcripts for DEXCOM.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more